INVESTOR HOME CORPORATE GOVERNANCE STOCK INFORMATION PRESS RELEASES EVENTS SEC FILINGS ANALYSTS INVESTOR FAQ PRODUCT DEMONSTRATIONS

Press Releases Keyword Search 2010 | 2009 | 2008 | 2007 | 2006 Date Title   07/20/10 Reminder: ADVENTRX Presents Today at the Lippert/Heilshorn Life Sciences & MedTech Virtual Conference 07/15/10 ADVENTRX Pharmaceuticals to Present at the Lippert/Heilshorn Life Sciences & MedTech Virtual Conference on July 20 07/14/10 Webcast Alert: ADVENTRX Pharmaceuticals, Inc. Announces LHA Life Sciences & Med Tech Day 2010 Presentation 06/30/10 ADVENTRX Announces 9-Month Stability Data Results for ANX-530 06/28/10 ADVENTRX Added to Russell Microcap Index 06/10/10 ADVENTRX Grants Exclusive Worldwide Rights to CoFactor Know-How and Data 05/10/10 ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on May 17 05/06/10 ADVENTRX Pharmaceuticals Announces Closing of Financing 05/03/10 ADVENTRX Pharmaceuticals Announces Financing 05/03/10 ADVENTRX Announces 6-Month Stability Data Results for ANX-530 04/30/10 ADVENTRX Reports First Quarter Financial Results 04/27/10 ADVENTRX to Resubmit ANX-530 NDA in the Fourth Quarter of 2010 04/26/10 ADVENTRX Reverse Split Effective; Trading on Adjusted Basis Begins Today 04/16/10 ADVENTRX Resolves NYSE Amex Listing Deficiencies 03/26/10 ADVENTRX Sets Meeting With FDA to Discuss ANX-530 NDA 03/16/10 ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results 03/12/10 ADVENTRX Receives Brand Name Acceptance for ANX-530 03/01/10 ADVENTRX Receives Refuse to File Letter from FDA on ANX-530 New Drug Application 02/04/10 ADVENTRX Announces Management Promotions 02/03/10 ADVENTRX Appoints Icahn Representative to Board of Directors 02/02/10 ADVENTRX Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference on February 9 01/07/10 ADVENTRX Pharmaceuticals Announces Closing of Financing 01/06/10 ADVENTRX Pharmaceuticals to Present at the OneMedForum Finance Conference on January 13 01/04/10 ADVENTRX Pharmaceuticals Announces Financing 01/04/10 ADVENTRX Pharmaceuticals Submits ANX-530 New Drug Application 12/09/09 ADVENTRX Pharmaceuticals to Present at the Lippert/Heilshorn Life Sciences Virtual Conference 12/01/09 ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 11/10/09 ADVENTRX Pharmaceuticals Reports Third Quarter Financial Results 10/22/09 ADVENTRX Pharmaceuticals to Present at the BIO Investor Forum on October 29 10/20/09 ADVENTRX Provides Business Update Following Recent Financing Activity 10/15/09 ADVENTRX Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26 10/09/09 ADVENTRX Pharmaceuticals Announces Closing of Financing 10/06/09 ADVENTRX Pharmaceuticals Announces Financing 09/14/09 ADVENTRX Intends Voluntary Withdrawal From NYSE Amex Upon Approval of NASDAQ Listing 08/12/09 ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 08/10/09 ADVENTRX Pharmaceuticals Announces Closing of Financing 08/05/09 ADVENTRX to Hold Second Quarter Results and Business Update Conference Call on August 12 08/05/09 ADVENTRX Pharmaceuticals Announces Financing 08/04/09 ADVENTRX Narrows Prior Guidance on NDA Submission Timeline 08/03/09 ADVENTRX Announces Acceptance of Compliance Plan by NYSE AMEX 07/06/09 ADVENTRX Pharmaceuticals Announces Closing of Financing 06/29/09 ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009 06/29/09 ADVENTRX Pharmaceuticals Announces Financing 06/15/09 ADVENTRX Pharmaceuticals Announces Closing of Financing 06/08/09 ADVENTRX Pharmaceuticals Announces Financing 06/02/09 ADVENTRX Receives Notice From NYSE Amex 05/12/09 ADVENTRX Pharmaceuticals Reports First Quarter 2009 Financial Results 05/07/09 ADVENTRX Announces Results From ANX-514 Bioequivalence Study 03/25/09 ADVENTRX Grants Exclusive Rights to ANX-514 in South Korea 03/25/09 ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 03/20/09 ADVENTRX Announces Further Cost-Cutting Measures 02/10/09 ADVENTRX Provides Update on Strategic Transaction Process 02/05/09 ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study 01/05/09 ADVENTRX Announces Further Cost-Cutting Measures 12/15/08 ADVENTRX Exploring Strategic Options 11/06/08 ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update 11/04/08 ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference 10/30/08 ADVENTRX Pharmaceuticals to Report Third Quarter 2008 Results 10/20/08 ADVENTRX Announces Restructuring and Cost Reduction Initiatives 08/11/08 ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update 08/08/08 ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results 07/01/08 ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R) 06/30/08 ADVENTRX Settles Dispute With Former Licensee 06/16/08 ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results 06/03/08 ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) 05/16/08 ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 05/13/08 ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 05/12/08 ADVENTRX Pharmaceuticals Reports First Quarter 2008 Financial Results 05/05/08 ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results 04/15/08 ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 04/09/08 ADVENTRX Appoints Vice President of Manufacturing 04/03/08 ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer 03/31/08 ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests 03/13/08 ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results 03/12/08 ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) 03/10/08 Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology 03/06/08 ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results 02/25/08 Eric K. Rowinsky Joins ADVENTRX Board of Directors 02/07/08 ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 02/05/08 ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference 01/31/08 ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference 01/30/08 ADVENTRX Announces Consolidation of Clinical and Management Positions 01/14/08 ADVENTRX Announces ANX-530 Safety Data and Provides NDA Submission Guidance 12/10/07 ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference 12/05/07 ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer 11/16/07 ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study 11/07/07 ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 11/05/07 ADVENTRX Pharmaceuticals to Present at the 13th Annual BIO-Europe Partnering Conference 11/02/07 ADVENTRX Provides Update on Cofactor(R) Program 11/01/07 ADVENTRX Pharmaceuticals to Present at the 9th Annual Acumen BioFin Rodman & Renshaw Healthcare Conference 10/31/07 ADVENTRX Pharmaceuticals to Present at the 18th Annual CIBC Healthcare Conference 10/30/07 ADVENTRX Pharmaceuticals to Present at the 2007 BIOCOM Investor Conference 10/25/07 ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests 10/10/07 ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study 10/08/07 ADVENTRX Appoints Vice President of Commercialization 10/05/07 ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum 10/01/07 ADVENTRX Pharmaceuticals Announces Results From Phase 2b Clinical Trial of ANX-510 (CoFactor(R)) 10/01/07 ADVENTRX Pharmaceuticals to Report Results from Phase 2b Clinical Trial of ANX-510 (Cofactor(R)) 09/27/07 ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 09/20/07 ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference 09/13/07 ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners' Fifth Annual Growth Conference 09/10/07 ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA 09/04/07 ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference 08/29/07 ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference 08/16/07 ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 08/02/07 ADVENTRX Pharmaceuticals Reports Second Quarter 2007 Financial Results 07/31/07 ADVENTRX Reschedules Conference Call and Webcast Discussion of Second Quarter 2007 Results to August 2, 2007 07/26/07 ADVENTRX Pharmaceuticals to Host Conference Call and Webcast Discussion of Second Quarter 2007 Results on August 3, 2007 07/23/07 ANX-201 Combination Therapy Demonstrates Synergistic Inhibition of HIV-1 in Preclinical Tests 06/12/07 Jack Lief Named Chairman of ADVENTRX Pharmaceuticals 06/07/07 ADVENTRX Pharmaceuticals Receives Designation as a Small/Medium Enterprise by the European Medicines Agency 05/24/07 ADVENTRX Executes Agreement With United States Department of Veterans Affairs 05/14/07 ADVENTRX Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference 05/09/07 ADVENTRX Pharmaceuticals to Present at Pharma Finance 2007 Conference 05/07/07 ADVENTRX Pharmaceuticals Reports First Quarter 2007 Financial Results 05/03/07 ANX-201 Drug Combination Demonstrates Synergistic Activity Against Human and Bird Flu Viruses 05/02/07 ADVENTRX Pharmaceuticals to Present at Biotechnology Industry Organization Annual Meeting 04/30/07 ADVENTRX Pharmaceuticals to Host Conference Call and Webcast Discussion of First Quarter 2007 Results on May 7, 2007 04/25/07 ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic Testing of ANX-514 (Docetaxel Emulsion) 04/23/07 ADVENTRX ANX-201 Abstract Accepted for Presentation at International AIDS Conference 04/18/07 ADVENTRX Announces Positive Data From Multidrug Therapy With CoFactor 04/11/07 ADVENTRX to Present at 7th Annual Fortis Biotech Conference 04/05/07 ADVENTRX Grants Manufacturing Contract for ANX-514 (Docetaxel Emulsion) 04/02/07 ADVENTRX to Present at CIBC Annual Biotechnology and Specialty Pharmaceuticals Conference 03/29/07 ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual Meeting 03/26/07 ADVENTRX and TRx Pharma Announce Zanaflu(R) Registered as the Brand Name for ANX-211 (Chitosan Gel) 03/20/07 ADVENTRX Awards Manufacturing Contract for ANX-201 (Thiovir(TM)) 03/15/07 ADVENTRX Pharmaceuticals, Inc. Announces Fourth Quarter and Year 2006 Financial Results 03/13/07 ADVENTRX Appoints Vice President of Regulatory Affairs 03/07/07 ADVENTRX Pharmaceuticals to Report Fourth Quarter and Full Year 2006 Financial Results on March 15, 2007 03/06/07 ADVENTRX Announces M. Ross Johnson to Retire as Board Chairman 02/28/07 ADVENTRX to Present at BIO-Europe Spring Conference 02/12/07 ADVENTRX to Present Thiovir Preclinical Data at the 20th International Conference on Antiviral Research 02/05/07 ADVENTRX to Present at BIO CEO Conference 01/22/07 ADVENTRX to Present at the American Stock Exchange First Annual Healthcare Conference 12/27/06 ADVENTRX Initiates CoFactor Phase II Clinical Trial in Refractory Breast Cancer 12/26/06 ADVENTRX Cleared to Initiate Vinorelbine Emulsion Bioequivalence Study 12/20/06 ADVENTRX Announces Appointment of Veteran Finance and Biotech Industry Executive Gregory P. Hanson as Chief Financial Officer 12/07/06 ADVENTRX to Participate at the RBC Capital Markets Healthcare Conference 11/14/06 ADVENTRX to Present at BIOCOM San Diego Investor Conference 11/10/06 ADVENTRX Completes $40 Million Sale of Common Stock 11/09/06 ADVENTRX Announces 2006 Third Quarter Financial Results 11/03/06 ADVENTRX Announces $40 Million Common Stock Offering 10/31/06 ADVENTRX to Present at November Investor and Partnering Conferences 10/26/06 ADVENTRX Announces Board Change 10/23/06 ADVENTRX Licenses Proprietary Antiviral Product to Theragenex 10/12/06 ADVENTRX to Present at the BIO InvestorForum 2006 09/25/06 ADVENTRX Completes Enrollment in CoFactor Phase IIb Metastatic Colorectal Cancer Trial 09/22/06 ADVENTRX Appoints Jack Lief as Director 09/18/06 ADVENTRX Presents Positive Data Regarding CoFactor Combination in Colorectal Tumor Model 09/11/06 ADVENTRX to Present at UBS Global Life Sciences Conference 09/08/06 ADVENTRX Announces Senior Management Changes 09/05/06 ADVENTRX to Present at Think Equity Growth Conference 08/16/06 ADVENTRX Appoints Vice President of Medical Affairs 08/10/06 ADVENTRX Announces 2006 Second Quarter Financial Results 08/09/06 ADVENTRX Announces Appointment of General Counsel 07/24/06 ADVENTRX to Present CoFactor and UFT Preclinical Results 07/12/06 ADVENTRX Announces Redemption of Warrants 06/29/06 ADVENTRX Presents Encouraging New Supplemental Results for the CoFactor Phase II Metastatic Colorectal Cancer Trial 06/29/06 ADVENTRX Presents CoFactor Pharmacokinetics Data 06/28/06 ADVENTRX Initiates CoFactor Phase III Clinical Trial 06/26/06 Data Safety Monitoring Board Recommends Continuation of ADVENTRX Phase IIb Clinical Trial for CoFactor 06/23/06 ADVENTRX to Present at Annual Euro-Biotech Forum 06/22/06 ADVENTRX Presents Broad Antiviral Activity for Thiovir 06/21/06 ADVENTRX Pharmaceuticals Set to Join Russell 3000 Index 06/20/06 ADVENTRX to Present Two CoFactor Clinical Abstracts at Gastrointestinal Cancer Conference 06/06/06 ADVENTRX to Present at the Pacific Growth Equities 2006 Life Sciences Growth Conference 06/05/06 ADVENTRX Announces Positive CoFactor Phase II Clinical Trial Results at ASCO Conference 05/30/06 ADVENTRX to Present CoFactor Phase II Results at ASCO Annual Conference 05/22/06 ADVENTRX Receives FDA Clearance Under a Special Protocol Assessment to Initiate CoFactor Phase III Clinical Trial 05/22/06 ADVENTRX Announces Withdrawal of Public Stock Offering 05/16/06 ADVENTRX Pharmaceuticals Announces Proposed Public Offering of Common Stock 05/10/06 ADVENTRX Announces 2006 First Quarter Financial Results 05/01/06 ADVENTRX Files Shelf Registration Statement 04/28/06 ADVENTRX Announces Closing of Merger With SD Pharmaceuticals 04/26/06 ADVENTRX to Present Positive Thiovir Antiviral Activity Results 04/13/06 ADVENTRX to Present at 6th Annual Fortis Bank Biotechnology Conference 04/10/06 ADVENTRX Signs Definitive Merger Agreement with SD Pharmaceuticals 04/06/06 ADVENTRX to Present at BIO 2006 Conference 04/05/06 ADVENTRX Presents Positive ANX-530 Preclinical Results 04/03/06 ADVENTRX Presents Positive Thiovir Preclinical Results 03/28/06 ADVENTRX Announces Upcoming Scientific Conference Presentations 03/23/06 ADVENTRX to Present at CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference 03/20/06 ADVENTRX Announces Thiovir Active Against H5N1 Avian Influenza Chimeric Virus Strains 03/20/06 ADVENTRX to File Amended 2005 Third Quarter to Reflect Accounting for July 2005 Financing Under EITF 00-19 03/16/06 ADVENTRX Announces 2005 Fourth Quarter and Full Year Financial Results 03/09/06 ADVENTRX to Present at Bear Stearns Conference 02/14/06 ADVENTRX CoFactor Phase IIb Trial Surpasses 50% Enrollment Milestone 02/03/06 ADVENTRX to Present at BIO CEO on February 14 01/31/06 ADVENTRX Reports Thiovir Active Against Various Influenza A Viruses in Series of Independent Preclinical Tests 01/30/06 ADVENTRX Announces Positive Efficacy and Safety Results from CoFactor Phase II Clinical Trial 01/23/06 ADVENTRX Thiovir Preclinical Studies Slated for Presentation at HIV Pathogenesis Conference 01/19/06 Results From ADVENTRX Vinorelbine Preclinical Studies Accepted for Presentation at AACR Annual Meeting 01/17/06 ADVENTRX to Present CoFactor Phase II Data at ASCO Gastrointestinal Cancer Conference 12/07/05 ADVENTRX Announces Positive FDA Pre-IND Meeting Outcome 12/01/05 ADVENTRX to Present at Informed Investors Bay Area Biotechnology and Healthcare Forum 11/14/05 ADVENTRX Announces 2005 Third Quarter Financial Results 11/02/05 ADVENTRX to Present at November Conferences 10/21/05 ADVENTRX Announces Positive CoFactor Study Data at AACR Special Conference in Cancer Research 10/13/05 ADVENTRX to Present at the BIO InvestorForum 2005 on October 19 10/10/05 ADVENTRX Reports Patient Enrollment Progress with CoFactor Phase IIb Trial 10/07/05 ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Techvest Healthcare Conference 10/06/05 ADVENTRX Reports Phase II CoFactor Trial Update 10/04/05 ADVENTRX Acquires Additional Oncology Drug Through Exclusive License Agreement 08/17/05 ADVENTRX to Present at the 2005 San Diego Growth Conference on August 19 08/12/05 ADVENTRX Announces 2005 Second Quarter Financial Results 08/12/05 ADVENTRX Expands Board Membership 08/01/05 ADVENTRX Completes $20 Million Private Placement with Carl Icahn as Largest Investor 07/26/05 ADVENTRX Presents Positive Thiovir Data at IAS 2005 Conference 07/22/05 ADVENTRX Pharmaceuticals Raises $20 Million in Common Stock Private Placement with Carl Icahn as Largest Investor 07/05/05 ADVENTRX Joins the New Russell Microcap Index 06/20/05 ADVENTRX Presents Response Data for Total Enrollment in CoFactor Phase II Metastatic Colorectal Cancer Trial 05/31/05 \Patient Treatment Initiated in ADVENTRX International Phase IIb Metastatic Colorectal Cancer Trial 05/13/05 ADVENTRX Announces 2005 First Quarter Financial Results 05/13/05 ADVENTRX Reports Positive Preliminary Phase II Trial Results with CoFactor in Metastatic Colorectal Cancer 05/02/05 ADVENTRX's Preliminary Results for CoFactor Phase II Trial Published at ASCO 04/28/05 ADVENTRX to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference on May 5 04/25/05 ADVENTRX Receives FDA Clearance for CoFactor Phase III Pivotal Trial in Metastatic Colorectal Cancer 04/19/05 ADVENTRX Presents Enhanced Antitumor Activity and Lower Systemic Toxicity with CoFactor Combination Therapies in Preclinical Models 04/15/05 ADVENTRX Granted Clearance in the UK for CoFactor Phase IIB Metastatic Colorectal Cancer Trial 04/11/05 ADVENTRX'S CoFactor Phase II and Preclinical Toxicity Data to be Presented at AACR Annual Meeting 04/04/05 ADVENTRX Announces 2004 Fourth Quarter and Full Year Financial Results 03/29/05 ADVENTRX Receives CoFactor Pancreatic Cancer Clinical Design and Protocol Final Advice Letter from EMEA 03/07/05 ADVENTRX Announces Primary Endpoint Met in Cofactor Phase II Metastatic Colorectal Cancer Trial 02/10/05 Bengt G. Gustavsson, M.D., Ph.D. To Chair ADVENTRX Scientific Advisory Board 01/25/05 Endpoints Met In First Stage Of ADVENTRX Cofactor Phase II Metastatic Colorectal Cancer Study 12/13/04 ADVENTRX Pharmaceuticals Announces Senior Management Appointments 12/01/04 ADVENTRX Pharmaceuticals to Present at Vaccines Conference 11/15/04 ADVENTRX Pharmaceuticals Announces Third Quarter 2004 Results 11/03/04 ADVENTRX Pharmaceuticals to Present at CIBC World Markets 15th Annual Healthcare Conference 11/02/04 FDA Clears CoFactor™ to Begin Second Stage of Phase II Clinical Trial for Metastatic Colorectal Cancer 10/22/04 ADVENTRX Pharmaceuticals to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference 10/14/04 CoFactor™ Granted Orphan Drug Status in the European Union for Pancreatic Cancer 10/11/04 ADVENTRX Pharmaceuticals to Present at the BIO Emerging Company Investor Forum 10/05/04 ADVENTRX Pharmaceuticals' Drug CoFactor™ Granted U.S. Orphan Drug Status by the FDA for Pancreatic Cancer 10/01/04 ADVENTRX Pharmaceuticals Announces CoFactor™ Results Showing Antitumor Activity with Lower Systemic Toxicity in a Colorectal Cancer Model 09/08/04 ADVENTRX Board of Directors Appoints Evan Levine President and CEO 08/10/04 ADVENTRX Pharmaceuticals Announces Second Quarter 2004 Results 07/22/04 ADVENTRX Pharmaceuticals Completes Move to New Facility 07/07/04 ADVENTRX Pharmaceuticals Initiates European Sites for its CoFactor Phase II Clinical Study 06/28/04 ADVENTRX Pharmaceuticals Presents Positive CoFactor™ Results in Pancreatic Tumor Model 06/28/04 ADVENTRX Pharmaceuticals Presents Positive CoFactor™ Results in Pancreatic Tumor Model 06/21/04 ADVENTRX Pharmaceuticals to Present at American Stock Exchange Annual Online Healthcare & Biotech Investor Conference 06/14/04 ADVENTRX Pharmaceuticals Plans Expansion and Move to New Facility 06/07/04 ADVENTRX Pharmaceuticals Announces Positive Findings for Combination CoFactor™, VEGF antibody and 5-FU in Colorectal Tumor Model 06/01/04 ADVENTRX Pharmaceuticals Commences cGMP Manufacturing of Thiovir™ 05/12/04 ADVENTRX Pharmaceuticals Reports Filing of Quarterly Report with the SEC and First Quarter 2004 Results 05/06/04 ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Techvest Global Healthcare Conference 05/04/04 First Patients Dosed with CoFactor™ in U.S. Phase II Clinical Trial for Metastatic Colorectal Cancer 04/29/04 American Stock Exchange Lists Common Stock Of Adventrx Pharmaceuticals, Inc. 04/27/04 ADVENTRX Pharmaceuticals To Be Listed On AMEX 04/26/04 ADVENTRX Pharmaceuticals to Webcast Presentation at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference 04/19/04 ADVENTRX Pharmaceuticals to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference 04/15/04 ADVENTRX Pharmaceuticals Receives FDA Clearance for HIV Viral Entry Inhibitor to Begin Phase Ib/IIa Human Clinical Trial 04/05/04 ADVENTRX Pharmaceuticals Announces Definitive Agreement for Sale of Common Stock 03/11/04 ADVENTRX Pharmaceuticals Adds Vice President of Clinical and Medical Affairs to Expand Clinical Trial Efforts 03/04/04 ADVENTRX Pharmaceuticals Files IND for Phase Ib/IIa Trials for HIV Viral Entry Inhibitor 02/20/04 ADVENTRX Pharmaceuticals Announces Notice of Government Grant Received by M.D. Anderson Cancer CenterADVENTRX Pharmaceuticals Announces Notice of Government Grant Received by M.D. Anderson Cancer Center 02/17/04 ADVENTRX Pharmaceuticals Elects New Member to the Board Of Directors 02/03/04 ADVENTRX Pharmaceuticals Announces Patent Granted for Eradicaide™ Technology to Diagnose, Prevent and Treat AIDS 01/29/04 ADVENTRX Pharmaceuticals Elects Two New Members to the Board of Directors 10/15/03 ADVENTRX Pharmaceuticals, Inc. Enters into Agreement with Leading Contract Research Organization for Phase II Clinical Trials of CoFactor™ 10/07/03 ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Techvest Healthcare Conference 10/02/03 ADVENTRX Pharmaceuticals Expands Preclinical Testing of second generation HIV Viral Entry Inhibitor 09/23/03 ADVENTRX Pharmaceuticals Expands HIV Antiviral Platform through development of Thiovir™ 09/16/03 ADVENTRX Pharmaceuticals Raises $2.5 Million Through a Private Placement 08/06/03 ADVENTRX Pharmaceuticals, Inc. Announces Formation of Scientific Advisory Board 07/22/03 ADVENTRX Pharmaceuticals, Inc. announces its Contract Research Organization Agreement for Phase Ib/IIa clinical trials for its HIV viral entry inhibitor 06/26/03 Company commences manufacturing of EradicAide– peptides in Preparation for IND Filing 06/13/03 Biokeys Pharmaceuticals Changes Name to ADVENTRX Pharmaceuticals, Inc. Company To Trade Under the Bulletin Board Symbol AVRX 06/11/03 Biokeys Pharmaceuticals, Inc. commences manufacturing of BlockAide/CR™ – Company Seeks to Duplicate Preclinical success in third quarter Phase Ib/IIa HIV Clinical Trial 06/05/03 Biokeys Pharmaceuticals, Inc. announces that it has initiated manufacturing of its Colorectal Cancer drug for Phase II human trials - Company Seeks to Replicate Success of Swedish Trials 05/28/03 Biokeys Pharmaceuticals, Inc. Completes Private Placement of Common Stock and Warrants 03/20/03 CEOcast Features Biokeys Pharmaceuticals' CEO 03/18/03 Research study discloses evidence that Biokeys Pharmaceuticals' viral entry inhibitor therapeutically targets diverse HIV-I strains 03/14/03 Biokeys Pharmaceuticals Inc. Hires Chief Technical Officer 02/10/03 Biokeys Pharmaceuticals Inc. Consolidates Operations to San Diego

COMPANY | PRODUCTS | CLINICAL TRIALS | PARTNERS | INVESTORS | NEWS | PUBLICATIONS | CONTACT HOME | CAREERS | SEARCH | SITE MAP | HELP | TERMS AND CONDITIONS | PRIVACY STATEMENT © Copyright 2009 ADVENTRX Pharmaceuticals